State Street
CTOR

State Street’s Citius Oncology CTOR Stock Holding History

State Street’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.6K Hold
42,900
– – ﹤0.01% 4194
2025
Q4 		$42.9K Hold
42,900
– – ﹤0.01% 4179
2025
Q3 		$87.1K Buy
+42,900
New +$92.9K ﹤0.01% 4076

Other funds holding CTOR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

State Street's CTOR Position: Q1 2026 in Review

State Street held its Citius Oncology (CTOR) position steady in Q1 2026 at 42,900 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4194.

State Street first reported a position in CTOR in Q3 2025 and has held it in 3 quarters since. The position peaked at $87.1K in Q3 2025. 14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

  • State Street held 42,900 shares of Citius Oncology worth $26.6K as of Q1 2026.
  • State Street left its Citius Oncology share count unchanged in Q1 2026.
  • Citius Oncology made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4194 holding.
  • State Street first reported a position in Citius Oncology in Q3 2025 and has held it in 3 quarters since.
  • State Street's Citius Oncology position peaked at $87.1K in Q3 2025.
  • 14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.